- Accession Number
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
Drug Drug Description Valrubicin An anthracycline used intravesically in the treatment of BCG-resistant bladder carcinoma. Epirubicin An anthracycline topoisomerase II inhibitor used as an adjuvant to treating axillary node metastases in patients who have undergone surgical resection of primary breast cancer. Daunorubicin An anthracycline aminoglycoside used to induce remission of nonlymphocytic leukemia and acute lymphocytic leukemia. Doxorubicin A medication used to treat various cancers and Kaposi's Sarcoma. Idarubicin An anthracycline antineoplastic agent used to treat acute myeloid leukemia (AML) in adults. Aldoxorubicin Investigated for use/treatment in solid tumors. Annamycin Investigated for use/treatment in breast cancer and leukemia (unspecified). Plicamycin For the treatment of testicular cancer, as well as hypercalcemia and hypercalciuria associated with a variety of advanced forms of cancer. Pirarubicin Not Annotated Aclarubicin Not Annotated Zorubicin Zorubicin is a drug of the anthracycline class - a class of medications that have historically demonstrated effective chemotherapy for a variety of cancer types. Sabarubicin Sabarubicin has been used in trials studying the treatment of Prostate Cancer, Testicular Germ Cell Tumor, and Unspecified Adult Solid Tumor, Protocol Specific. Zoptarelin doxorubicin Zoptarelin doxorubicin has been used in trials studying the treatment of Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, and Urothelial Carcinoma, among others. GPX-150 GPX-150 has been used in trials studying the treatment of Soft Tissue Sarcoma and Advanced Solid Tumors - Phase 1 Population. SP1049C Intended for the treatment of carcinoma of the oesophagus. DTS-201 Investigated for use/treatment in cancer/tumors (unspecified). Gancotamab Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients). Nanoparticle Epirubicin Nanoparticle Epirubicin is under investigation in clinical trial NCT03168061 (Dose-escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma).
- Drugs & Drug Targets